ARMP vs PHGE vs LSTA vs SIGA vs ACXP

For growth investors, Armata Pharmaceuticals, Inc.

(ARMP) is the stronger pick with 14. 2% revenue growth year-over-year, versus -83. 0% for Lisata Therapeutics, Inc. (LSTA). SIGA Technologies, Inc. (SIGA) offers the better valuation at 14. 3x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Armata Pharmaceuticals, Inc.

(ARMP) delivered a total return of +119. 4%, compared to -99. 9% for BiomX Inc. (PHGE). Over 10 years, the gap is even starker: SIGA returned +772. 1% versus PHGE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BiomX Inc.

(PHGE) is the lower-risk stock at 1. 05β versus Acurx Pharmaceuticals, Inc. 's 2. 31β — meaning ACXP is approximately 120% more volatile than PHGE relative to the S&P 500.

By revenue growth (latest reported year), Armata Pharmaceuticals, Inc.

(ARMP) is pulling ahead at 14. 2% versus -83. 0% for Lisata Therapeutics, Inc. (LSTA). On earnings-per-share growth, the picture is similar: Armata Pharmaceuticals, Inc. grew EPS 72. 6% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, ARMP leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SIGA Technologies, Inc.

(SIGA) is the more profitable company, earning 24. 6% net margin versus -97. 6% for Lisata Therapeutics, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus -107. 1% for LSTA. At the gross margin level — before operating expenses — SIGA leads at 68. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PHGE: 6037.

9% to $38. 00.

In this comparison, SIGA (12.

7% yield) pays a dividend. ARMP, PHGE, LSTA, ACXP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), 12. 7% yield, +772. 1% 10Y return). Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +772. 1%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ARMP is a small-cap quality compounder stock; PHGE is a small-cap quality compounder stock; LSTA is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; ACXP is a small-cap quality compounder stock. SIGA pays a dividend while ARMP, PHGE, LSTA, ACXP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.